| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10037679 | HBV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS10031602 | HBV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS10025527 | HBV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS10024806 | HBV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS10049406 | HBV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS10049407 | HBV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS30000179 | HIV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS30077807 | HIV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS30020975 | HIV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
| TVIS20031120 | HPV | ENSG00000106804.10 | protein_coding | C5 | No | No | 727 | P01031 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | C5 |
|---|---|
| DrugBank ID | DB16416 |
| Drug Name | Vilobelimab |
| Target ID | BE0000855 |
| UniProt ID | P01031 |
| Regulation Type | inhibitor |
| PubMed IDs | 33015643; 28366510 |
| Citations | Vlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, Kemper EM, van der Horst ICC, Schultz MJ, Horn J, Paulus F, Bos LD, Wiersinga WJ, Witzenrath M, Rueckinger S, Pilz K, Brouwer MC, Guo RF, Heunks L, van Paassen P, Riedemann NC, van de Beek D: Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020 Dec;2(12):e764-e773. doi: 10.1016/S2665-9913(20)30341-6. Epub 2020 Sep 28.@@Riedemann NC, Habel M, Ziereisen J, Hermann M, Schneider C, Wehling C, Kirschfink M, Kentouche K, Guo R: Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition. Clin Immunol. 2017 Jul;180:25-32. doi: 10.1016/j.clim.2017.03.012. Epub 2017 Mar 30. |
| Groups | Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
